Metabolic risk factors are associated with non‐hepatitis B non‐hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B

Shiu‐Feng Huang, Il‐Chi Chang, Chih‐Chen Hong, Tseng‐Chang Yen, Chao‐Long Chen, Cheng‐Chung Wu, Cheng‐Chung Tsai, Ming‐Chih Ho, Wei‐Chen Lee, Hsien‐Chung Yu, Ying‐Ying Shen, Hock‐Liew Eng, John Wang, Hui‐Hwa Tseng, Yung‐Ming Jeng, Chau‐Ting Yeh, Chi‐Ling Chen, Pei‐Jer Chen, Yun‐Fan Liaw – 18 April 2018 – Metabolic risk factors, such as obesity, fatty liver, high lipidemia, and diabetes mellitus are associated with increased risk for nonviral hepatocellular carcinoma (HCC); however, few nonviral HCC studies have stratified patients according to underlying etiologies.

Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease

Francesca Romana Ponziani, Sherrie Bhoori, Chiara Castelli, Lorenza Putignani, Licia Rivoltini, Federica Del Chierico, Maurizio Sanguinetti, Daniele Morelli, Francesco Paroni Sterbini, Valentina Petito, Sofia Reddel, Riccardo Calvani, Chiara Camisaschi, Anna Picca, Alessandra Tuccitto, Antonio Gasbarrini, Maurizio Pompili, Vincenzo Mazzaferro – 17 April 2018 – The gut–liver axis plays a pivotal role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), which is the third leading cause of hepatocellular carcinoma (HCC) worldwide.

Prevalence, Risk Factors, and Impact of Donor‐Specific Alloantibodies After Adult Liver Transplantation

Katia Vandevoorde, Stéphanie Ducreux, Alexie Bosch, Olivier Guillaud, Valérie Hervieu, Christine Chambon‐Augoyard, Domitille Poinsot, Patrice André, Jean‐Yves Scoazec, Philip Robinson, Olivier Boillot, Valérie Dubois, Jérôme Dumortier – 17 April 2018 – The incidence and impact of anti–human leukocyte antigen donor‐specific alloantibodies (DSAs) developing after liver transplantation (LT) remains controversial and not extensively studied.

The adenosine monophosphate–activated protein kinase—vacuolar adenosine triphosphatase–pH axis: A key regulator of the profibrogenic phenotype of human hepatic stellate cells

Giusi Marrone, Francesco De Chiara, Katrin Böttcher, Ana Levi, Dipok Dhar, Lisa Longato, Giuseppe Mazza, Zhenzhen Zhang, Martina Marrali, Anabel Fernández‐Iglesias, Andrew Hall, Tu Vinh Luong, Benoit Viollet, Massimo Pinzani, Krista Rombouts – 17 April 2018 – Liver fibrosis and cirrhosis are characterized by activation of hepatic stellate cells (HSCs), which is associated with higher intracellular pH (pHi). The vacuolar H+ adenosine‐triphosphatase (v‐ATPase) multisubunit complex is a key regulator of pHi homeostasis.

Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease

Francesca Romana Ponziani, Sherrie Bhoori, Chiara Castelli, Lorenza Putignani, Licia Rivoltini, Federica Del Chierico, Maurizio Sanguinetti, Daniele Morelli, Francesco Paroni Sterbini, Valentina Petito, Sofia Reddel, Riccardo Calvani, Chiara Camisaschi, Anna Picca, Alessandra Tuccitto, Antonio Gasbarrini, Maurizio Pompili, Vincenzo Mazzaferro – 17 April 2018 – The gut–liver axis plays a pivotal role in the pathogenesis of nonalcoholic fatty liver disease (NAFLD), which is the third leading cause of hepatocellular carcinoma (HCC) worldwide.

Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival

Fang Wang, Thomas Bank, Gregory Malnassy, Maribel Arteaga, Na Shang, Annika Dalheim, Xianzhong Ding, Scott J. Cotler, Mitchell F. Denning, Michael I. Nishimura, Peter Breslin, Wei Qiu – 17 April 2018 – Hepatocellular carcinoma (HCC) is the fifth most common primary cancer and second largest cause of cancer‐related death worldwide. The first‐line oral chemotherapeutic agent sorafenib only increases survival in patients with advanced HCC by less than 3 months. Most patients with advanced HCC have shown limited response rates and survival benefits with sorafenib.

Subscribe to